CEREPHARMA
ActiveSummary
CEREPHARMA has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €933,614 and a net result of €91,805. Equity is growing by about 19% per year across the filed financial years. Its solvency ranks better than 68% of 92 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- CEREPHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Région wallonne” (deed in French)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Six ans, 3” (deed in French)3 more provisions on this in the deed
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Actions,droits de préférence,droits de souscription et obligations convertibles émis par la société ou donnant droit à des actions émises…” (deed in French)
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Décision de l’assemblée générale délibérant comme en matière de modification aux statuts” (deed in French)